Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02865811 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT02865811: Completed Phase 2 study, sponsored by Dana-Farber Cancer Institute.
NCT02865811 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 26 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02865811, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This research study is studying the combination of Pegylated Liposomal Doxorubicin (PLD) and Pembrolizumab as a possible treatment for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer that is resistant to platinum therapy. The following interventions will be used in this study: * Pegylated liposomal doxorubicin (PLD) * Pembrolizumab
Primary Outcome
The primary objective was to determine the CBR (complete response \[CR\] + partial response \[PR\] + stable disease \[SD\] \>/= 24 weeks) of the combination of pembrolizumab and PLD.
Interventions
- DRUG Pembrolizumab
- DRUG Pegylated Liposomal Doxorubicin (PLD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-09-15 |
| Est. Completion | 2022-03 |
| Phase | Phase 2 |
What the finished NCT02865811 record still lists
NCT02865811 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02865811 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02865811 about?
NCT02865811 is a clinical study titled "Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer". This research study is studying the combination of Pegylated Liposomal Doxorubicin (PLD) and Pembrolizumab as a possible treatment for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer that is resistant to platinum therapy. The following interventions will be used in this study: * Pegylated l...
What is the current status of trial NCT02865811?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2016-09-15. Estimated completion is 2022-03.
What interventions are being tested in trial NCT02865811?
The interventions under investigation include: Pembrolizumab (DRUG), Pegylated Liposomal Doxorubicin (PLD) (DRUG).
Who is sponsoring clinical trial NCT02865811?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02865811's enrollment target sits among peer trials
26 1708th of 2000 higher than 282 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI